• Home

  • HEALTH CARE

  • HEALTHY LIFESTYLE

  • HYGIENE

  • COSMETICS

  • FOR HIM

  • PREGNANCY AND MOTHERHOOD

  • CHILD

    2. HEALTH CARE
    3. Vanatex 160mg 28 tablets — Made in Poland by Polpharma — Free Delivery

    Vanatex 160mg 28 tablets — Made in Poland by Polpharma — Free Delivery


    Brand: POLPHARMA
    Product Code: Vanatex 160mg
    Availability: In Stock
    $26.50
    Add to Cart

    Indications

    • Arterial hypertension treatment of hypertension in adults.
    • postinfarction condition. Treatment of clinically stable patients with symptomatic heart failure or asymptomatic left ventricular systolic dysfunction after a recent (12 h–10 days) myocardial infarction.
    • Heart failure. Treatment of symptomatic heart failure when ACE inhibitors cannot be used, or as adjuvant therapy with ACE inhibitors when β-adrenergic receptor blockers cannot be used.

    Application

    Valsartan can be taken with or without food, with water.
    AG. The recommended initial dose of valsartan is 80 mg (1 tablet Vanatex 80 mg or ½ tablet Vanatex 160 mg) once a day. The antihypertensive effect is achieved in the first 2 weeks, and the maximum effect is observed within 4 weeks.
    In some patients whose blood pressure is not well controlled, the dose can be increased to 160 mg, up to a maximum of 320 mg.
    Valsartan can be taken with other antihypertensive preparations.
    The addition of a diuretic such as hydrochlorothiazide further lowers blood pressure in these patients.
    postinfarction condition. Treatment of clinically stable patients can be started using valsartan as early as 12 hours after myocardial infarction. After an initial dose of 20 mg twice daily, the dose of valsartan should be increased to 40; 80 and 160 mg twice a day for the next few weeks. Vanatex is not prescribed for initial treatment. To achieve smaller doses (20 mg), you should take the preparation in a different dosage form. The maximum dose is 160 mg 2 times a day. It is recommended that a dose of 80 mg twice a day be reached 2 weeks after the start of treatment, and a maximum dose of 160 mg 2 times a day - after 3 months, taking into account the tolerability of the patient. If symptomatic hypotension or renal dysfunction occurs, dose reduction should be considered.
    Valsartan can be used in patients who have taken other preparations after myocardial infarction, such as thrombolytics, acetylsalicylic acid, β-blockers, statins and diuretics. Combination with ACE inhibitors is not recommended. Evaluation of the condition of patients after myocardial infarction should always include a study of kidney function.
    Heart failure. The recommended starting dose of valsartan is 40 mg twice daily. It is necessary to increase the dose to 80 and 160 mg 2 times a day at intervals of at least 2 weeks, taking into account the tolerability of the preparation by the patient. Consideration should be given to reducing the dose of concomitant diuretics. The maximum daily dose that was prescribed was 320 mg and was divided into several doses.
    Valsartan may be taken with other medicines to treat heart failure. However, the triple combination of an ACE inhibitor, a beta-blocker and valsartan is not recommended. Evaluation of patients with heart failure should always include an examination of renal function.
    Additional information regarding special patient groups
    Elderly patients. Dose adjustment is not required for elderly patients.
    Patients with renal insufficiency. Dose adjustment is not required for patients with a creatinine clearance of 10 ml/min.
    Patients with liver failure. For patients with mild to moderate hepatic impairment without cholestasis, the dose of valsartan should not exceed 80 mg. Valsartan is contraindicated in patients with severe hepatic impairment and in patients with cholestasis.

    Contraindications

    Hypersensitivity to the active substance or any of the excipients. severe liver failure, cirrhosis and cholestasis.

    Side effects

    Classified by frequency: very often (≥1/10); often (1/100, ≤1/10); sometimes (1/1000, ≤1/100); rarely (1/10,000, ≤1/1000); very rarely (1/10,000), including single messages. Within each group, adverse reactions are presented in order of decreasing severity.
    For all adverse reactions reported in post-marketing and laboratory studies, one of the above frequencies cannot be applied, and therefore their frequency is indicated as “unknown”.
    AG
    On the part of the blood and lymphatic system: unknown - a decrease in hemoglobin, a decrease in hematocrit, neutropenia, thrombocytopenia.
    From the immune system: unknown - hypersensitivity, including serum sickness.
    From the side of metabolism: unknown - an increase in the level of potassium in the blood plasma, hyponatremia.
    On the part of the organ of hearing and balance: infrequently - dizziness.
    From the side of the vessels: unknown - vasculitis.
    From the respiratory system: infrequently - cough.
    From the digestive tract: infrequently - abdominal pain.
    From the side of the liver and gallbladder: unknown - an increase in liver function, including an increase in the level of bilirubin in the blood plasma.
    From the skin and subcutaneous tissues: unknown - Quincke's edema (angioneurotic edema), rash, itching.
    From the musculoskeletal system and connective tissue: unknown - myalgia.
    From the side of the kidneys and urinary tract: unknown - acute renal failure and impaired renal function, increased plasma creatinine levels.
    General disorders: infrequently - increased fatigue.
    Adverse reactions that have occurred in patients after myocardial infarction and / or heart failure are listed below.
    After myocardial infarction and/or heart failure
    On the part of the blood and lymphatic system: unknown - thrombocytopenia.
    From the immune system: unknown - hypersensitivity, including serum sickness.
    From the side of metabolism: infrequently - hyperkalemia; unknown - increase in the level of potassium in the blood plasma, hyponatremia.
    From the nervous system: often - dizziness, postural dizziness; infrequently - fainting, headache.
    On the part of the organ of hearing and balance: infrequently - dizziness.
    From the side of the heart: infrequently - heart failure.
    From the side of the vessels: often - arterial hypotension, orthostatic hypotension; unknown - vasculitis.
    From the respiratory system: infrequently - cough.
    From the digestive system: infrequently - nausea, diarrhea.
    From the side of the liver and gallbladder: unknown - increased activity of liver enzymes, increased plasma bilirubin concentration.
    From the skin and subcutaneous tissues: infrequently - Quincke's edema (angioneurotic edema); unknown - rash, itching.
    From the musculoskeletal system and connective tissue: unknown - myalgia.
    From the side of the kidneys and urinary tract: often - renal failure and impaired renal function; infrequently - acute renal failure, increased plasma creatinine levels; unknown - increased blood urea nitrogen.
    General disorders: infrequently - asthenia, fatigue.

    special instructions

    Hyperkalemia. concomitant use with potassium supplements, potassium-sparing diuretics, salt substitutes containing potassium, or other agents that may increase potassium levels (heparin, etc.) is not recommended. if necessary, it is necessary to monitor the content of potassium in the blood.
    Patients with sodium deficiency. In patients with severe sodium deficiency, for example, those taking high doses of diuretics, symptomatic arterial hypotension may rarely occur at the beginning of treatment. Before starting treatment, the sodium content in the body should be corrected, for example, by reducing the dose of a diuretic.
    Patients with hypovolemia. Symptomatic arterial hypotension can rarely occur in patients with severe hypovolemia taking high doses of diuretics after initiation of valsartan therapy. Hypovolaemia must be corrected before starting treatment with valsartan, for example, by reducing the dose of the diuretic.
    Stenosis of the renal artery. In patients with bilateral renal artery stenosis or stenosis of one kidney, the safe use of valsartan has not been established.
    Short-term administration of valsartan in patients with renovascular hypertension due to unilateral renal artery stenosis did not cause any significant changes in renal hemodynamics, plasma creatinine or urea nitrogen. However, other preparations that affect the renin-angiotensin system can increase blood urea and plasma creatinine levels in patients with unilateral renal artery stenosis, so monitoring of renal function is recommended if the patient is taking valsartan.
    Kidney transplant. To date, there is no experience with the safe use of valsartan in patients who have recently undergone kidney transplantation.
    Primary hyperaldosteronism. In patients with primary hyperaldosteronism, valsartan should not be used because their renin-angiotensin system is not activated.
    Stenosis of the aortic and mitral valves, obstructive hypertrophic cardiomyopathy. As with other vasodilators, special care must be taken when treating patients with aortic or mitral valve stenosis or hypertrophic obstructive cardiomyopathy.
    Impaired kidney function. No dose adjustment is required for patients with a creatinine clearance of 10 ml/min. To date, there is no experience with the safe use of valsartan in patients with a creatinine clearance of 10 ml / min and patients on dialysis, so valsartan should be administered with caution to such patients.
    Liver failure. In patients with mild to moderate hepatic impairment without cholestasis, valsartan should be administered with caution.
    Recent myocardial infarction. The combination of captopril and valsartan does not show additional clinical benefits, while the risk of side effects is increased compared to that of treatment with the respective agents. Thus, the combined use of valsartan with an ACE inhibitor is not recommended. Caution should be exercised at the beginning of treatment of patients after myocardial infarction. Evaluation of the condition of patients after myocardial infarction should always include a study of kidney function.
    The use of valsartan in patients after a myocardial infarction generally leads to some decrease in blood pressure, but discontinuation of treatment due to prolonged symptomatic hypotension is usually not necessary if dosage recommendations are followed.
    Heart failure. The use of a triple combination of an ACE inhibitor, a beta-blocker and valsartan in patients with heart failure does not demonstrate any clinical benefit. This combination obviously increases the risk of side effects and is therefore not recommended.
    Caution should be exercised at the start of treatment in patients with heart failure. Evaluation of patients with heart failure should always include a study of renal function.
    The use of valsartan in patients with heart failure generally leads to some decrease in blood pressure, but discontinuation of treatment due to prolonged symptomatic hypotension is usually not necessary if the dosage instructions are followed. In patients whose renal function depends on the activity of the renin-angiotensin system (for example, in patients with severe congestive / acute heart failure), treatment with ACE inhibitors is associated with oliguria and / or progressive azotemia and, in some cases, with acute renal failure and / or death. Since valsartan is an Ang II antagonist, it cannot be ruled out that the use of valsartan may be associated with impaired renal function.
    Excipients. The preparation contains lactose (1 tablet 80 mg contains 56.5 mg lactose monohydrate, 1 tablet 160 mg contains 113 mg lactose monohydrate). Patients with rare hereditary problems of galactose intolerance, lactase deficiency or glucose-galactose malabsorption syndrome should not use this preparation.
    Use during pregnancy and lactation
    Pregnancy. The use of Ang II receptor antagonists is not recommended during the entire period of pregnancy
    Before starting the preparation, women of reproductive age should be examined to exclude a possible pregnancy. If a woman wishes to become pregnant, the preparation should be discontinued and replaced with any other antihypertensive preparation that has an established safety profile for use during pregnancy. In the event that pregnancy is confirmed during treatment, it should be switched as soon as possible (under the supervision of a physician) to alternative therapeutic agents that pose a lower risk to the fetus.
    Lactation. Due to lack of information, the use of valsartan is not recommended during breastfeeding.
    Children. Valsartan is not recommended for use in children (under 18 years of age) due to lack of data on its safety and efficacy.
    The ability to influence the reaction rate when driving vehicles or working with other mechanisms. No studies have been conducted on the effect on the ability to drive vehicles. When driving vehicles or working with other mechanisms, it must be taken into account that dizziness or increased fatigue may sometimes occur.

    Interactions

    Simultaneous use is not recommended
    Lithium. Reversible increases in plasma lithium concentrations and toxicity have been reported with concomitant use of ACE inhibitors. Due to the lack of experience with the simultaneous use of valsartan and lithium, this combination is not recommended. If such a combination proves necessary, careful monitoring of the level of lithium in the blood plasma is recommended.
    Potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium, and other substances that can increase potassium levels. If a preparation that affects potassium levels is to be combined with valsartan, monitoring of plasma potassium levels is recommended.
    Caution should be exercised with the simultaneous use of NSAIDs, including selective COX-2 inhibitors, acetylsalicylic acid (3 g / day) and non-selective NSAIDs. With the simultaneous appointment of Ang II antagonists and NSAIDs, the antihypertensive effect may be weakened. In addition, the simultaneous use of Ang II antagonists and NSAIDs may lead to an increased risk of worsening kidney function and an increase in plasma potassium levels. Thus, it is recommended to monitor renal function at the beginning of treatment, as well as to carry out appropriate hydration of the patient.
    Other types of interactions. The study did not establish any clinically significant interactions of valsartan with any of the following substances: cimetidine, warfarin, furosemide, digoxin, atenolol, indomethacin, hydrochlorothiazide, amlodipine, glibenclamide.

    Overdose

    Symptoms. an overdose of valsartan can lead to severe arterial hypotension, which, in turn, can cause depression of consciousness, circulatory collapse (vascular insufficiency) and / or shock (coma).
    Treatment. Therapeutic measures depend on the time of eating, as well as the type and severity of symptoms, stabilization of blood circulation is extremely important.
    In case of arterial hypotension, the patient should be in the supine position, while it is necessary to correct the BCC. It is unlikely that valsartan is excreted by hemodialysis.

    Storage conditions

    In a dry place at a temperature not exceeding 25 ° C. Keep out of the reach of children.

    There are no reviews for this product.
    VEV Healthcare Store © 2017